Johns Hopkins ABX Guide
Ibrexafungerp
INDICATIONS
FDA
FDA
- Ibrexafungerp is indicated for the treatment of vulvovaginal candidiasis (VVC) in adults and post-menarchal pediatric females.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 7, 2022
Citation
Dzintars, Kathryn. "Ibrexafungerp." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp.
Dzintars K. Ibrexafungerp. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp. Accessed April 24, 2024.
Dzintars, K. (2022). Ibrexafungerp. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp
Dzintars K. Ibrexafungerp [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 April 24]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ibrexafungerp
ID - 540761
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2022/08/07/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
